New Clinical Study With Diamyd Medical AB's Diabetes Vaccine

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Diamyd Medical AB (STO:DIAMB) (Pink Sheets:DMYDY) reports that a new clinical study with the diabetes vaccine Diamyd® is planned to start in February 2013. In the study Diamyd® will be tested in a unique combination with other drugs, aiming to potentiate the effect of the diabetes vaccine. The Company has entered into an agreement with Linköping University to conduct the researcher-initiated study. The study has been approved by the Swedish Medical Products Agency. The study, which is the first study of its kind, combines the diabetes vaccine Diamyd® with relatively high doses of vitamin D and the anti-inflammatory drug ibuprofen. The purpose of the treatment is to preserve the body's own ability to control the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes.

Back to news